share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Gallman Cari

SEC announcement ·  Mar 13 08:04
Summary by Futu AI
On March 10, 2024, Cari Gallman, EVP of Corporate Affairs at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Gallman acquired a total of 2,761 shares through the exercise or conversion of derivative securities at no cost. On the same day, Gallman disposed of 1,535 shares. The disposals included shares used to cover exercise prices or tax liabilities, with some transactions priced at $53.79 per share, totaling a market value of $37,437.84. Following these transactions, Gallman's direct holdings in Bristol-Myers Squibb common stock amounted to 1,432 shares.
On March 10, 2024, Cari Gallman, EVP of Corporate Affairs at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Gallman acquired a total of 2,761 shares through the exercise or conversion of derivative securities at no cost. On the same day, Gallman disposed of 1,535 shares. The disposals included shares used to cover exercise prices or tax liabilities, with some transactions priced at $53.79 per share, totaling a market value of $37,437.84. Following these transactions, Gallman's direct holdings in Bristol-Myers Squibb common stock amounted to 1,432 shares.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.